Brief: Altimmune Inc Phase 2 AUD Trial For Pemvidutide Expected In Q2 2025
13/03/2025 21:33
March 13 (Reuters) - Altimmune Inc ALT.O: ALTIMMUNE INC - PHASE 2 AUD TRIAL FOR PEMVIDUTIDE EXPECTED IN Q2 2025 Further company coverage: ALT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Altimmune
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat
U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial (updated)